Current status of moleculartargeted drugs for endometrial cancer (Review)

By Nogami Yuya   Banno Kouji   Kisu Iori   Yanokura Megumi   Umene Kiyoko   Masuda Kenta   Kobayashi Yusuke   Yamagami Wataru   Nomura Hiroyuki   Tominaga Eiichiro   Susumu Nobuyuki   Aoki Daisuke  

Molecular and Clinical Oncology, Vol. 1, Iss. 5, 2013-09 ,pp. : 799-804

Spandidos Publications

Access to resources Recommend Favorite

Circulating Regulatory T Cells in Endometrial Cancer: A Role for Age and Menopausal Status

By Sawan Saladin   Burt Deborah J.   Stern Peter L.   Holland Cathrine   Elkord Eyad  

Immunological Investigations, Vol. 40, Iss. 1, 2011-01 ,pp. : 62-75

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of Topoisomerase I by Anti-Cancer Drug Altered the Endometrial Cyclicity and Receptivity

By  

Current Molecular Medicine, Vol. 14, Iss. 1, 2014-01 ,pp. : 141-150

Bentham Science Publishers

Access to resources Recommend Favorite

Fluorescence in Situ Hybridization Analysis of HER-2/neu, c-myc, and p53 in Endometrial Cancer

By Williams J.A.   Wang Z.-R.   Parrish R.S.   Hazlett L.J.   Smith S.T.   Young S.R.  

Experimental and Molecular Pathology, Vol. 67, Iss. 3, 1999-12 ,pp. : 135-143

Elsevier

Access to resources Recommend Favorite

Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells

By Fujisawa T.   Watanabe J.   Kamata Y.   Hamano M.   Hata H.   Kuramoto H.  

Experimental and Molecular Pathology, Vol. 74, Iss. 3, 2003-06 ,pp. : 276-281

Elsevier

Access to resources Recommend Favorite